TY - JOUR AU - Cardinale, J. PY - 2016 DA - 2016// TI - Preclinical evaluation of [18F]PSMA-1007: a new PSMA-ligand for prostate cancer imaging JO - J Nucl Med VL - 27 ID - Cardinale2016 ER - TY - JOUR AU - Chen, Y. PY - 2011 DA - 2011// TI - 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-11-1357 DO - 10.1158/1078-0432.CCR-11-1357 ID - Chen2011 ER - TY - JOUR AU - Malik, N. PY - 2011 DA - 2011// TI - Radiosynthesis of a new PSMA targeting ligand ([18F]FPy-DUPA-Pep) JO - Appl Radiat Isot VL - 69 UR - https://doi.org/10.1016/j.apradiso.2011.03.041 DO - 10.1016/j.apradiso.2011.03.041 ID - Malik2011 ER - TY - JOUR AU - Cho, S. Y. PY - 2012 DA - 2012// TI - Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer JO - J Nucl Med VL - 53 UR - https://doi.org/10.2967/jnumed.112.104661 DO - 10.2967/jnumed.112.104661 ID - Cho2012 ER - TY - JOUR AU - Malik, N. PY - 2015 DA - 2015// TI - Radiofluorination of PSMA-HBED via Al(18)F(2+) chelation and biological evaluations in vitro JO - Mol Imaging Biol VL - 17 UR - https://doi.org/10.1007/s11307-015-0844-6 DO - 10.1007/s11307-015-0844-6 ID - Malik2015 ER - TY - JOUR AU - Lapi, S. E. PY - 2009 DA - 2009// TI - Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer JO - J Nucl Med VL - 50 UR - https://doi.org/10.2967/jnumed.109.066589 DO - 10.2967/jnumed.109.066589 ID - Lapi2009 ER - TY - JOUR AU - Rowe, S. P. PY - 2016 DA - 2016// TI - PSMA-based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer JO - Mol Imaging Biol VL - 18 UR - https://doi.org/10.1007/s11307-016-0957-6 DO - 10.1007/s11307-016-0957-6 ID - Rowe2016 ER - TY - JOUR AU - Mease, R. C. PY - 2008 DA - 2008// TI - N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-1517 DO - 10.1158/1078-0432.CCR-07-1517 ID - Mease2008 ER - TY - JOUR AU - Szabo, Z. PY - 2015 DA - 2015// TI - Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer JO - Mol Imaging Biol VL - 17 UR - https://doi.org/10.1007/s11307-015-0850-8 DO - 10.1007/s11307-015-0850-8 ID - Szabo2015 ER - TY - JOUR AU - Afshar-Oromieh, A. PY - 2015 DA - 2015// TI - The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions JO - J Nucl Med VL - 56 UR - https://doi.org/10.2967/jnumed.115.161299 DO - 10.2967/jnumed.115.161299 ID - Afshar-Oromieh2015 ER - TY - JOUR AU - Giesel, F. L. PY - 2017 DA - 2017// TI - F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients JO - Eur J Nucl Med Mol Imaging VL - 44 UR - https://doi.org/10.1007/s00259-016-3573-4 DO - 10.1007/s00259-016-3573-4 ID - Giesel2017 ER - TY - JOUR AU - Eiber, M. PY - 2017 DA - 2017// TI - Prostate-specific membrane antigen ligands for imaging and therapy JO - J Nucl Med VL - 58 UR - https://doi.org/10.2967/jnumed.116.186767 DO - 10.2967/jnumed.116.186767 ID - Eiber2017 ER - TY - JOUR AU - Kularatne, S. A. PY - 2009 DA - 2009// TI - Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents JO - Mol Pharm VL - 6 UR - https://doi.org/10.1021/mp9000712 DO - 10.1021/mp9000712 ID - Kularatne2009 ER - TY - JOUR AU - Hillier, S. M. PY - 2013 DA - 2013// TI - 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer JO - J Nucl Med VL - 54 UR - https://doi.org/10.2967/jnumed.112.116624 DO - 10.2967/jnumed.112.116624 ID - Hillier2013 ER - TY - JOUR AU - Giesel, F. L. PY - 2016 DA - 2016// TI - 18F-labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617 JO - Eur J Nucl Med Mol Imaging VL - 43 UR - https://doi.org/10.1007/s00259-016-3447-9 DO - 10.1007/s00259-016-3447-9 ID - Giesel2016 ER - TY - JOUR AU - Valko, K. PY - 2003 DA - 2003// TI - Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity JO - J Pharm Sci VL - 92 UR - https://doi.org/10.1002/jps.10494 DO - 10.1002/jps.10494 ID - Valko2003 ER - TY - JOUR AU - Weineisen, M. PY - 2014 DA - 2014// TI - Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer JO - EJNMMI Res VL - 4 UR - https://doi.org/10.1186/s13550-014-0063-1 DO - 10.1186/s13550-014-0063-1 ID - Weineisen2014 ER - TY - BOOK AU - Neumaier, B. AU - Zlatopolskiy, B. AU - Richarz, R. AU - Krapf, P. PY - 2016 DA - 2016// TI - Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a Psma-specific pet-tracer ID - Neumaier2016 ER - TY - JOUR AU - Richarz, R. PY - 2014 DA - 2014// TI - Neither azeotropic drying, nor base nor other additives: a minimalist approach to (18)F-labeling JO - Org Biomol Chem VL - 12 UR - https://doi.org/10.1039/C4OB01336K DO - 10.1039/C4OB01336K ID - Richarz2014 ER - TY - JOUR AU - Chen, Y. PY - 2008 DA - 2008// TI - Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer JO - J Med Chem VL - 51 UR - https://doi.org/10.1021/jm801055h DO - 10.1021/jm801055h ID - Chen2008 ER - TY - JOUR AU - Bouvet, V. PY - 2016 DA - 2016// TI - Automated synthesis of [(18)F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models JO - EJNMMI Res VL - 6 UR - https://doi.org/10.1186/s13550-016-0195-6 DO - 10.1186/s13550-016-0195-6 ID - Bouvet2016 ER - TY - JOUR AU - Bacich, D. J. PY - 2001 DA - 2001// TI - Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase JO - Mamm Genome VL - 12 UR - https://doi.org/10.1007/s003350010240 DO - 10.1007/s003350010240 ID - Bacich2001 ER - TY - JOUR AU - Hlouchova, K. PY - 2012 DA - 2012// TI - GCPII variants, paralogs and orthologs JO - Curr Med Chem VL - 19 UR - https://doi.org/10.2174/092986712799462676 DO - 10.2174/092986712799462676 ID - Hlouchova2012 ER - TY - JOUR AU - Eder, M. PY - 2014 DA - 2014// TI - Novel preclinical and radiopharmaceutical aspects of [(68)Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer JO - Pharmaceuticals VL - 7 UR - https://doi.org/10.3390/ph7070779 DO - 10.3390/ph7070779 ID - Eder2014 ER - TY - JOUR AU - Weineisen, M. PY - 2015 DA - 2015// TI - 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies JO - J Nucl Med VL - 56 UR - https://doi.org/10.2967/jnumed.115.158550 DO - 10.2967/jnumed.115.158550 ID - Weineisen2015 ER - TY - JOUR AU - Liu, T. PY - 2008 DA - 2008// TI - Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics JO - Biochemistry VL - 47 UR - https://doi.org/10.1021/bi801883v DO - 10.1021/bi801883v ID - Liu2008 ER - TY - JOUR AU - Rajasekaran, S. A. PY - 2003 DA - 2003// TI - A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen JO - Mol Biol Cell VL - 14 UR - https://doi.org/10.1091/mbc.E02-11-0731 DO - 10.1091/mbc.E02-11-0731 ID - Rajasekaran2003 ER - TY - JOUR AU - Benesova, M. PY - 2016 DA - 2016// TI - Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors JO - J Med Chem VL - 59 UR - https://doi.org/10.1021/acs.jmedchem.5b01210 DO - 10.1021/acs.jmedchem.5b01210 ID - Benesova2016 ER - TY - JOUR AU - Wustemann, T. PY - 2016 DA - 2016// TI - Design of internalizing PSMA-specific Glu-ureido-based radiotherapeuticals JO - Theranostics VL - 6 UR - https://doi.org/10.7150/thno.13448 DO - 10.7150/thno.13448 ID - Wustemann2016 ER - TY - STD TI - Benesova M, et al. PSMA-617-a novel theranostic PSMA inhibitor for both diagnosis and endoradiotherapy of prostate cancer. J Nuc Med. 2015;56(3) ID - ref30 ER - TY - STD TI - Schottelius M, et al. [111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015;5(1) ID - ref31 ER - TY - JOUR AU - Eder, M. PY - 2014 DA - 2014// TI - Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer JO - Prostate VL - 74 UR - https://doi.org/10.1002/pros.22784 DO - 10.1002/pros.22784 ID - Eder2014 ER -